Manforce is a particularly easy sildenafil brand to misidentify because Mankind Pharma uses the name in product records covering more than one active-ingredient composition. An Indian pharmacy listing identifies Manforce 50 mg Tablet as sildenafil 50 mg and Mankind Pharma Limited as marketer. Mankind’s own product catalogue also includes Manforce entries involving sildenafil alone and a sildenafil–dapoxetine combination.
There is a further naming complication: the company catalogue separately names Super Manforce with tadalafil. That means an isolated search result for “Manforce,” “Manforce combo” or “Super Manforce” should not be treated as evidence of a plain sildenafil tablet. The complete product name and ingredients matter more than the shared brand stem.
This page separates those documented identities, product-company roles and implications for U.S. readers. It does not endorse an Indian seller or merge combination drugs into FDA-approved sildenafil generics. For U.S. product information visit generic sildenafil; for other India-market brands use the Indian brand directory.
Mankind Pharma’s published product list names MANFORCE for sildenafil citrate and for dapoxetine hydrochloride with sildenafil citrate. It also lists SUPER MANFORCE as tadalafil. An Indian pharmacy entry separately identifies Manforce 50 mg as sildenafil 50 mg. Together, these records demonstrate why copying the trade-name root from a search result is insufficient to determine medicine identity.
The table reports company and pharmacy entries without assuming that all similarly named products are interchangeable or that an exact combination can be prescribed safely to a given patient.
| Documented name / record | Ingredient statement | Why the distinction matters |
|---|---|---|
| Manforce 50 mg Tablet | Sildenafil 50 mg; Indian pharmacy names Mankind Pharma as marketer | Specific sildenafil-only retail product record |
| MANFORCE (company portfolio) | Sildenafil citrate | Mankind’s official portfolio includes single-ingredient formulation |
| MANFORCE (company portfolio) | Sildenafil citrate + dapoxetine hydrochloride | Separate combination composition; not plain sildenafil |
| SUPER MANFORCE (company portfolio) | Tadalafil | Different active ingredient according to the published portfolio |
| Manforce consumer-product branding | Non-prescription product lines may share the name | Brand familiarity alone does not identify a prescription medicine |
The official Mankind Pharma brand list is unusually useful here because it lays out more than one active-ingredient entry under a related name. This is stronger evidence than guessing from the word “Super” that a product is always sildenafil plus dapoxetine. The company’s records support separate descriptions of sildenafil-only, combination and tadalafil-labelled products.
The list is a product-family guide, not an approval certificate for each finished pack. Strength, package size, manufacturing site and exact role can vary by item and should not be invented where the list does not provide them.
An Indian pharmacy catalog lists Manforce 50 mg Tablet as containing sildenafil 50 mg and identifies Mankind Pharma Limited as marketer. This supports a narrow, useful statement: there is a documented India-market Manforce 50 tablet with a declared sildenafil ingredient. It does not establish that every Manforce variant contains sildenafil 50 mg.
A reader looking up Manforce 50 should distinguish the tablet label from the general brand family and from any combination product. Its Indian dispensing record cannot supply FDA equivalence, personal dosing advice or legal U.S. availability.
The Mankind portfolio’s sildenafil–dapoxetine entry introduces an entirely separate active ingredient from sildenafil-only Manforce. Dapoxetine has its own drug-effect and interaction considerations; the combination is not simply a “higher dose” of sildenafil. A medication history assessed for sildenafil alone may not address all the risks of a two-drug product.
This page documents the existence of the composition category without giving instructions on combining medicines. A seller that abbreviates the combination as “Manforce” while hiding the full formula does not provide enough information to identify what is being offered.
Mankind’s product list includes SUPER MANFORCE with tadalafil, a distinct PDE5 inhibitor. This is particularly important because online descriptions of “super” products can vary across catalogues and markets. The official portfolio entry prevents the editorial mistake of automatically classifying every Super Manforce search result as sildenafil or sildenafil–dapoxetine.
A product-specific label still takes precedence over a short commercial description. Sildenafil and tadalafil have different dosing schedules and interaction considerations, so substitution based on a similar trade name is unsafe. The separate sildenafil versus tadalafil comparison explains their ingredient-level differences.
Manforce is widely encountered as a consumer-facing name in India beyond the narrow ED tablet category. That visibility increases the chances that a search, advertisement or picture refers to a different item altogether. The intended medicine can only be identified by the complete name, composition and dosage form; the brand’s popularity provides no clinical evidence.
Editorially, a product labelled “Manforce” without an ingredient statement should be treated as incomplete information. Copying its picture into a prescription product comparison would risk mixing unrelated merchandise with actual tablets.
No such conclusion follows from the Indian Manforce records. FDA-approved sildenafil tablets are evaluated as specific U.S. products with identifiable applications and labeling. A foreign product whose composition resembles a U.S. drug does not receive the same approval automatically. A tadalafil-labelled Super Manforce product is a different active ingredient altogether.
For domestic product identity use FDA-approved generic sildenafil or the U.S. Viagra brand guide. The useful purpose of this page is to resolve Manforce naming and formulation ambiguities, not to market foreign products as U.S. generics.
Sildenafil-only Manforce products would carry the ingredient’s serious risks with nitrates and riociguat and warrant review of cardiovascular conditions and other medications. A sildenafil–dapoxetine combination presents additional interaction questions. A tadalafil-labelled item should not be managed as though it were a sildenafil tablet just because both are PDE5 inhibitors.
Anyone experiencing an erection longer than four hours needs urgent medical attention. The distinct sildenafil interaction guide and side effects guide cover the sildenafil component only, not complete safety guidance for every Manforce-branded composition.
First establish the complete printed product name; then read every declared active ingredient, the strength of each ingredient and the dosage form. Compare those facts with the company or pharmacy record relevant to that exact name. If a seller provides only “Manforce strong tablets” without composition, the item has not been identified reliably.
A second company’s marketing photograph does not prove who manufactured the finished pack. Treat promoter, marketer and manufacturer as separate roles where the evidence does not expressly merge them. The documented Manforce 50 pharmacy entry specifies marketer, not a universal manufacturer for every similar product.
Both Manforce and Suhagra have credible product listings with sildenafil-only and combination names, but the decisive details differ. Cipla explicitly provides Suhagra Force ingredient amounts in its corporate table, while Mankind’s published portfolio distinguishes a Manforce sildenafil–dapoxetine composition and Super Manforce tadalafil. Those differences should stay visible in any brand comparison.
For U.S. patients, importing unapproved prescription products is generally not a routine legal way to fill an ED prescription. The U.S. sildenafil access guide covers clinician assessment and licensed dispensing of FDA-approved medicines.
An Indian pharmacy product record identifies Manforce 50 mg Tablet as sildenafil 50 mg with Mankind Pharma Limited named as marketer.
No. Mankind’s company portfolio also identifies a Manforce sildenafil–dapoxetine composition.
The company’s published portfolio lists Super Manforce with tadalafil. A particular marketed package still requires identity checks.
No. The documented product names are associated with different ingredient statements.
No. Adding a different active ingredient changes the medicine; it is not equivalent to increasing sildenafil strength.
The identified Indian pharmacy record names Mankind Pharma Limited as marketer. Manufacturing details for any exact pack require separate documentation.
The identified India-market Manforce product records do not establish FDA approval of that branded product in the United States.
By clinician evaluation and dispensing of an appropriate FDA-approved prescription product at a licensed U.S. pharmacy.